Phase 2 Epilepsy Trial, Recruiting NCT07363603 Sponsor: Pirogov Russian National Research Medical University Condition: Epilepsy
Back to Epilepsy

Phase 2 Epilepsy Trial, Recruiting

NCT07363603
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A parent or legal guardian must provide written consent before any study activities begin, and the child must also give their agreement to participate where appropriate for their age and understanding.
  • Children who are aged 1 year old up to (but not including) 14 years old at the time consent is signed, of any sex.
  • People who have a confirmed genetic change called c.607G>A in the GNAO1 gene, along with both epilepsy and movement disorders as part of their condition.
  • People whose seizures have continued despite trying at least two appropriately dosed seizure medications at separate times.
  • People whose involuntary movements or dystonic episodes (sudden, severe movement problems) have continued despite trying at least two appropriately dosed medications aimed at controlling those movements.
  • Post-menarchal female adolescents (those who have started their period) must have a negative pregnancy test at the start of the study and must agree to use highly effective contraception throughout their participation.

Who may not be able to join:

  • People who have another serious medical, neurological, or psychiatric condition, or unstable health, that the trial doctor believes could increase risks or affect the study results.
  • People who have an anatomical abnormality, a blood clotting disorder, an active infection, or any other condition that would make it unsafe to receive the study drug through repeated injections into the spine (lumbar punctures).
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • People who have received another experimental drug, device, or biological treatment within 1 month before screening, or within 5 half-lives of that product — whichever is the longer period.
  • People who have any other disease, condition, or behavioural factor that the trial doctor believes could affect safety, make it difficult to follow the study schedule, or interfere with how the study is conducted or assessed.
  • People who are 14 years of age or older.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Elena D Belousova, Prof, Pirogov Russian National Research Medical University

Phone: +7 (499) 487-54-51

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Pirogov Russian National Research Medical University
Registry
ClinicalTrials.gov
Start date
9 September 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Change in monthly seizure frequency; Change in total monthly duration of seizures; Change in frequency of non-epileptic hyperkinetic and dystonic episodes; Change in duration of non-epileptic hyperkinetic and dystonic episodes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov